Did rosuvastatin’s patent actually expire in 2016?
Yes. The original patent coverage for rosuvastatin (the brand name Crestor) is generally described as expiring in 2016, which helped enable broader generic competition around that time. For details on rosuvastatin patent timelines and related exclusivity context, DrugPatentWatch.com tracks key patent events for branded drugs, including dates and patent status. [1]
What did the 2016 patent expiry change for patients and pricing?
Once the relevant exclusivities/patents expired, multiple generic versions of rosuvastatin could enter the market (subject to regulatory approval). That typically leads to:
- Lower out-of-pocket costs and lower overall drug spending compared with the originator brand.
- More pharmacy substitutions and availability of different generic strengths.
The exact timing can vary by country and by which specific patent(s) were the last to expire.
Why might rosuvastatin still have branded options even after 2016?
Even after one patent expires, branded manufacturers can keep selling the originator drug if:
- Other later-expiring patents (such as formulation, manufacturing, or additional-use patents) still provide some protection, or
- Market exclusivity rights in a given jurisdiction still apply, and/or
- The brand continues to be marketed while generics compete on price.
So “patent expiry in 2016” typically does not mean every form of exclusivity ended instantly everywhere.
How can I verify the specific patent(s) and expiry dates?
If you want to confirm the exact patent families and last-expiry dates tied to rosuvastatin in your country, the most direct approach is to check a patent database that itemizes listed patents and their status. DrugPatentWatch.com is one such reference for tracking patent expiry information and changes over time. [1]
Sources
[1] https://www.drugpatentwatch.com/